Navigation Links
aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics business, announced today that aTyr has received two industry awards from TiE and San Diego Venture Group (SDVG) for innovation in life sciences.  The awards recognize the advancements aTyr has made in discovering and developing first-in-class opportunities based on Physiocrine biology. Physiocrines represent new protein therapeutic horizons for auto-immune patients.  

The two awards from TiE and SDVG were competitive on a global and a local level, respectively, and sought to identify and recognize the companies that best represented innovation in a range of industries. TiE, a not-for-profit global network of entrepreneurs and professionals, screened more than 2,100 companies from 37 countries to select 50 of the best companies in five areas: mobile, clean tech, software, social networking and life sciences. aTyr won the award in life sciences for the company's innovation, ingenuity, strong management team and quality of ideas. aTyr was also recently recognized as a "Cool Company" by SDVG which selected, from 150 nominees, 30 companies that represented innovation across all industry sectors in San Diego. 

To learn more about aTyr Pharma, Dr. John Mendlein, aTyr's executive chairman and CEO, will be speaking on a panel called, "Beyond Antibodies: Developing Next Generation Biologics" at the upcoming BIO International Convention in Boston, MA.  The panel will take place June 21 from 8:30 am to 9:45 am EDT in Room 253B. 

About Physiocrines
Physiocrines are produced from ancient genes, aminoacyl tRNA synthetases, an intercellular gene family involved in protein synthesis. Overlooked by genomic discovery efforts, Physiocrines are naturally occurring proteins that modulate extracellular signaling pathways in a variety of physiological processes. These endogenous human proteins act through a variety of receptor classes via mechanisms distinct from current pharmaceuticals and have potential applications in a number of therapeutic areas. aTyr is focused on using Physiocrines to generate effective physiologic responses in immune system disorders, including inflammation and disordered immunity.

About aTyr Pharma
aTyr Pharma develops biologic therapeutics based on Physiocrine biology. aTyr has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr's key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
4. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
5. Genesis Biopharma Mentioned Favorably in BioMedReports Article
6. Genesis Biopharma Issues Letter To Shareholders
7. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
8. Questcor Pharmaceuticals Expands Repurchase Program
9. PharmAthene Reports First Quarter 2012 Financial Results
10. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
11. PDL BioPharma to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology:
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):